



ARTEMIS

The Power of Virtual Twins to Fight MAFLD

PRESS RELEASE

ARTEMIS: Accelerating the Translation of virtual twins towards a personalized Management of fatty liver patients

ARTEMIS, an ambitious EU-funded research initiative, launches to revolutionize the management of Metabolic dysfunction-associated fatty liver disease (MAFLD).

ARTEMIS was launched on the 1st of January with the aim of making a major leap forward in the management of **MAFLD**. The leading cause of chronic liver disease (CLD) in Europe surpassing viral hepatitis and alcohol-related causes.

ARTEMIS' promising approach aims to control this fast-growing metabolic syndrome and its complications by leveraging advanced liver and heart **Virtual Twins**. For this purpose, the project will co-design, develop, and evaluate a **clinical decision support system** (CDSS) for application in the clinical management of MAFLD patients.

"Despite the progress of research, many questions remain open about the evolution and treatment of MAFLD: I am convinced that digital twins have their role to play in finding answers to these questions and understanding the impact on other organs such as the heart", affirms Irène Vignon-Clémentel; Scientific Coordinator (INRIA).

To advance knowledge in this field, the European Union (EU), through the Horizon Europe (HE) programme, will invest **10 million euros in ARTEMIS over the next 4 years**. Thanks to this EU-funded project, a powerful tool to help decision-making towards improved patient management strategies, personalized diagnostics, and innovative therapeutic strategies will be developed. ARTEMIS has the ambition to enable early disease detection, prediction of disease progression, and effective disease management. This will ultimately contribute to promoting **Real-World Data** and **AI for secure and ethical decision-making in healthcare** in alignment with some of the most ambitious EU goals in terms of healthcare digitalization in the coming years.

"ARTEMIS is grounded upon three building blocks: a multimodal and regulatory-grade MAFLD cohort, liver and heart Virtual Twins, and a user-friendly Smart Dashboard", expressed Cristina d'Almeida, ARTEMIS' Consortium Building Leader.





ARTEMIS

The Power of Virtual Twins to Fight MAFLD

A multidisciplinary effort for a more personalised management of MAFLD

The project, which holds its first meeting on **February 7th, in Paris** at Parisanté Campus, brings together a unique combination of expertise to address the complexities of consolidating existing computational models to deliver 'virtual twins' embedded in a CDSS. 22 European and non-European internationally recognised institutions — hospitals, academia, regulatory experts, high-tech SMEs and a patient association— from 9 countries will join forces to revolutionize the management of MAFLD.

"ARTEMIS embodies a collaborative effort that transcends boundaries. February 7 marks the beginning of a journey that will undoubtedly redefine MAFLD patient care and contribute significantly to the EU goals. We are excited to embark on this transformative path with our dedicated partners," stated Mario Aznar, ARTEMIS' Project Coordinator.

ARTEMIS Consortium Partners

AP-HP (Henri Mondor, Paul Brousse, and Pitié Salpêtrière Hospitals), Betthera, Bournemouth University, Charité, Cliniques Universitaires Saint-Luc, German Cancer Research Center (DKFZ), European Liver Patients' Association (ELPA), Heidelberg University Hospital, Imperial College Healthcare (NHS trust), National Institute for Research in Digital Science and Technology (INRIA), Institute of Cardiometabolism and Nutrition (ICAN), Jena University Hospital, La Fe Health Research Institute, Leipzig University, Matical, Medical University of Vienna, Medexprim, Sapienza University of Rome, Sant'Andrea University Hospital, Sheba Medical Center, Vall d'Hebron Research Institute.

About Horizon Europe

ARTEMIS is funded by Horizon Europe - HORIZON-HLTH-2023-TOOL-05-03: "Integrated multi-scale computation models of patient patho-physiology ("virtual twins") for personalised disease management". Horizon Europe is the European Union's flagship research and innovation program to secure Europe's technological leadership globally with a budget of €95.5 billion. The program supports collaborative projects addressing societal challenges and driving innovation across various domains, creating jobs, boosting economic growth, promoting industrial competitiveness, and optimizing investment impact within a strengthened European Research Area. Legal entities from the EU and associated countries can participate. To learn more: <https://research-and-innovation.ec.europa.eu/>

Disclaimer

This press release is for informational purposes only. The information herein is subject to change without notice. The ARTEMIS consortium and its partners do not assume any liability for the accuracy or completeness of the information provided.

Learn more: ARTEMIS' [LinkedIN page](#)

For media inquiries, please contact: l.munoz@matical.com

The ARTEMIS Project is funded by the European Union within the Horizon Europe program under grant agreement No 101136299.

